Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

BACKGROUND AND PURPOSE Cannabidiol (CBD) and Δ9‐tetrahydrocannabinol (THC) interact with transient receptor potential (TRP) channels and enzymes of the endocannabinoid system.

[1]  A. Lichtman,et al.  Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. , 2010, Drug and alcohol dependence.

[2]  T. Uyama,et al.  N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). , 2010, Progress in lipid research.

[3]  E. Sher,et al.  Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity. , 2010, European journal of pharmacology.

[4]  Mahmoud A. ElSohly,et al.  Potency Trends of Δ9‐THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008 * , 2010, Journal of forensic sciences.

[5]  S. Petrosino,et al.  N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. , 2010, Biochimie.

[6]  M. Cascio,et al.  The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice , 2010, British journal of pharmacology.

[7]  T. Shippenberg,et al.  The Nonpsychoactive Cannabinoid Cannabidiol Inhibits 5-Hydroxytryptamine3A Receptor-Mediated Currents in Xenopus laevis Oocytes , 2010, Journal of Pharmacology and Experimental Therapeutics.

[8]  A. Finizio,et al.  Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter , 2010, PloS one.

[9]  Z. Ackerman,et al.  Cannabidiol ameliorates cognitive and motor impairments in bile‐duct ligated mice via 5‐HT1A receptor activation , 2010, British journal of pharmacology.

[10]  T. Bisogno,et al.  Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. , 2010, Bioorganic & medicinal chemistry letters.

[11]  G. Yount,et al.  Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival , 2010, Molecular Cancer Therapeutics.

[12]  R. Pertwee,et al.  Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1A receptor antagonist , 2010, British journal of pharmacology.

[13]  L. Petrocellis,et al.  Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels , 2010, Journal of Neuroimmune Pharmacology.

[14]  S. Cuzzocrea,et al.  Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation , 2009, Proceedings of the National Academy of Sciences.

[15]  J. Després,et al.  CB1 antagonists for obesity—what lessons have we learned from rimonabant? , 2009, Nature Reviews Endocrinology.

[16]  Daniele Piomelli,et al.  Discovery of potent and reversible monoacylglycerol lipase inhibitors. , 2009, Chemistry & biology.

[17]  R. Capasso,et al.  Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. , 2009, Trends in pharmacological sciences.

[18]  T. Bisogno,et al.  Synthesis and Pharmacological Activity of a Potent Inhibitor of the Biosynthesis of the Endocannabinoid 2‐Arachidonoylglycerol , 2009, ChemMedChem.

[19]  G. Bidaux,et al.  Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. , 2009, Biochimica et Biophysica Acta.

[20]  L. Steardo,et al.  Cannabidiol: A Promising Drug for Neurodegenerative Disorders? , 2009, CNS neuroscience & therapeutics.

[21]  B. Platt,et al.  Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+ Levels , 2009, The Journal of Neuroscience.

[22]  A. Akopian,et al.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. , 2009, Trends in pharmacological sciences.

[23]  F. Guimarães,et al.  5‐HT1A receptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats , 2009, British journal of pharmacology.

[24]  H. Pan,et al.  Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death , 2008, Journal of Pharmacology and Experimental Therapeutics.

[25]  R. Capasso,et al.  Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice , 2008, British journal of pharmacology.

[26]  T. Hutchinson,et al.  TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons , 2008, The Journal of Neuroscience.

[27]  V. Vellani,et al.  Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[28]  F. Guimarães,et al.  Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats , 2008, Psychopharmacology.

[29]  A. Akopian,et al.  Cannabinoids Desensitize Capsaicin and Mustard Oil Responses in Sensory Neurons via TRPA1 Activation , 2008, The Journal of Neuroscience.

[30]  Y. Kitamura,et al.  Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism , 2008, Brain Research.

[31]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[32]  B. Costa,et al.  The inhibition of monoacylglycerol lipase by URB602 showed an anti‐inflammatory and anti‐nociceptive effect in a murine model of acute inflammation , 2007, British journal of pharmacology.

[33]  Michael Zhao,et al.  TRPA1 mediates formalin-induced pain , 2007, Proceedings of the National Academy of Sciences.

[34]  J. Levine,et al.  TRP channels: targets for the relief of pain. , 2007, Biochimica et biophysica acta.

[35]  L. Battistin,et al.  Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL‐2H3 mast cells , 2007, Journal of leukocyte biology.

[36]  T. Hutchinson,et al.  Activation Properties of Heterologously Expressed Mammalian TRPV2 , 2007, Journal of Biological Chemistry.

[37]  V. Di Marzo,et al.  Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. , 2007, Experimental cell research.

[38]  J. Desroches,et al.  The antinociceptive effects of intraplantar injections of 2‐arachidonoyl glycerol are mediated by cannabinoid CB2 receptors , 2007, British journal of pharmacology.

[39]  R. Pertwee,et al.  Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro , 2007, British journal of pharmacology.

[40]  M. García-Arencibia,et al.  Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties , 2007, Brain Research.

[41]  B. Costa,et al.  The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. , 2007, European journal of pharmacology.

[42]  A. Patapoutian,et al.  A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition , 2007, Molecular pain.

[43]  M. Tominaga,et al.  Lipophilicity of capsaicinoids and capsinoids influences the multiple activation process of rat TRPV1. , 2006, Life sciences.

[44]  I. Matias,et al.  Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma , 2006, Journal of Pharmacology and Experimental Therapeutics.

[45]  C. Hillard,et al.  Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Platt,et al.  Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells , 2006, Neuropharmacology.

[47]  A. Lichtman,et al.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity , 2006, Psychopharmacology.

[48]  G. Uhl,et al.  Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain , 2006, Brain Research.

[49]  T. Bisogno,et al.  Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. , 2006, Biochimica et biophysica acta.

[50]  G. Guy,et al.  A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. , 2006, Medical hypotheses.

[51]  M. Elsohly,et al.  Chemical constituents of marijuana: the complex mixture of natural cannabinoids. , 2005, Life sciences.

[52]  R. Pertwee,et al.  Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist , 2005, British journal of pharmacology.

[53]  K. Mackie,et al.  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .

[54]  E. Russo,et al.  Agonistic Properties of Cannabidiol at 5-HT1a Receptors , 2005, Neurochemical Research.

[55]  J. Crystal,et al.  An endocannabinoid mechanism for stress-induced analgesia , 2005, Nature.

[56]  L. Petrocellis,et al.  The biosynthesis, fate and pharmacological properties of endocannabinoids. , 2005, Handbook of experimental pharmacology.

[57]  B. Lutz,et al.  Further evidence for the existence of a specific process for the membrane transport of anandamide. , 2004, The Biochemical journal.

[58]  P. Massi,et al.  Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines , 2004, Journal of Pharmacology and Experimental Therapeutics.

[59]  D. Parolaro,et al.  Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[60]  D. McKemy,et al.  Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1 , 2004, Nature.

[61]  Gareth Williams,et al.  Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain , 2003, The Journal of cell biology.

[62]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Ponde,et al.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.

[64]  N. Ueda,et al.  Purification and Characterization of an Acid Amidase Selective for N-Palmitoylethanolamine, a Putative Endogenous Anti-inflammatory Substance* , 2001, The Journal of Biological Chemistry.

[65]  R. Mechoulam.  Looking back at Cannabis research. , 2000, Current pharmaceutical design.

[66]  I. Yamamoto,et al.  Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. , 1998, Life sciences.

[67]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[68]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[69]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[70]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[71]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[72]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[73]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[74]  M. Elsohly,et al.  Biological Activity of Cannabichromene, its Homologs and Isomers , 1981, Journal of clinical pharmacology.

[75]  W. M. Davis,et al.  Cannabichromene and Δ9-tetrahydrocannabinol: Interactions relative to lethality, hypothermia and hexobarbital hypnosis , 1981 .

[76]  R. Sofia,et al.  Comparative anti-phlogistic activity of delta 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models. , 1974, Life sciences.

[77]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[78]  R. Mechoulam,et al.  Hashish. I. The structure of cannabidiol. , 1963, Tetrahedron.